

TGN
PLSR
250 TID
350 BID
150 TID
0 24 48 72 96 120 144 168
1000 2000 3000 4000 5000
FCA6
FCA1
Plasma Concentration [ng/ml] median and 90 %Pi
time [hr]

FIGURE 1




Screening/randomizatio
Treatment Period 1
Washout
Treatment Period 2
Follow-up
BIIB074
400 mg bid repeat
dose (Male subjects)
300 mg bid repeat
dose (Female
Placebo
BIIB074 400 mg
single dose*
(Female subjects)
30 days
Period 1
Baseline visit
36 days
7 days
Period 2
Baseline visit
36 days
7–14 days
Protocol:
Timeline
*Administered 7 days prior to treatment period 1 baseline visit

FIGURE 2

A


Mean Change over 24 h in Systolic Blood Pressure from Baseline to Day 36 (Outpatient)
Mean (SD) in clb SBP (mmHg)
Time (h) relative to a.m. dosing
Placebo
GSK1014802 300-400 mg BD

B




Mean Change over 24 h in Diastolic Blood Pressure from Baseline to Day 36 (Outpatient)
Mean (SD) in clb DBP (mmHg)
Time (h) relative to a.m. dosing
Placebo
GSK1014802 300-400 mg BD

FIGURE 3

A


Proportion of Change from Baseline Observations of Interest in Systolic Blood Pressure over 24 h on Day 36 (Outpatient)
Percentage
0
10
20
30
40
50
<-30
>=-30 to <=-20
>-20 to <=-10
>-10 to <=0
>0 to <=10
>10 to <=20
>20 to <=30
>30
Change from Baseline in SBP (mmHg)
Placebo
GSK1014802 300-400 mg RD

B




Proportion of Change from Baseline Observations of Interest in Diastolic Blood Pressure over 24 h on Day 36 (Outpatient)
Percentage
0
10
20
30
40
<-20
>=-20 to <=-15
>-15 to <=-10
>-10 to <=-5
>-5 to <=0
>0 to <=5
>5 to <=10
>10 to <=15
>15 to <=20
>20
Change from Baseline in SBP (mmHg)
Placebo
GSK1014802 300-400 mg RD

FIGURE 4

A


Mean Change over 12 h in Systolic Blood Pressure from Baseline to Day 35 (Inpatient)
Mean (SD) in -ve SBP (mmHg)
10
8
6
4
2
0
-2
-4
-6
-8
-10
0
6
12
Time (h) relative to a.m. dosing
Placebo
GSK1014802 300-400 mg BD

B




Mean Change over 12 h in Diastolic Blood Pressure from Baseline to Day 35 (Inpatient)
Mean (SD) in +ve DBP (mmHg)
10
8
6
4
2
0
-2
-4
-6
-8
-10
0
6
12
Time (h) relative to a.m. dosing
Placebo
GSK1014802 300-400 mg BD

FIGURE 5


SBP standing (mmHg)
200
180
160
140
120
100
80
60
Conc. (ng/mL)
0
2000
4000
6000
8000



DBP standing (mmHg)
180
160
140
120
100
80
60
40
20
Conc. (ng/mL)
0
2000
4000
6000
8000

FIGURE 6